GB2448224B - Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent - Google Patents

Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent

Info

Publication number
GB2448224B
GB2448224B GB0805991A GB0805991A GB2448224B GB 2448224 B GB2448224 B GB 2448224B GB 0805991 A GB0805991 A GB 0805991A GB 0805991 A GB0805991 A GB 0805991A GB 2448224 B GB2448224 B GB 2448224B
Authority
GB
United Kingdom
Prior art keywords
reduction
effects
pharmaceutical composition
orally administered
administered pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0805991A
Other languages
English (en)
Other versions
GB0805991D0 (en
GB2448224A (en
Inventor
Maryka Quik
Donato Di Monte
J William Langston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parkinsons Institute
Original Assignee
Parkinsons Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parkinsons Institute filed Critical Parkinsons Institute
Priority to GB0912941A priority Critical patent/GB2461412B/en
Priority to GB1008749A priority patent/GB2468424B/en
Publication of GB0805991D0 publication Critical patent/GB0805991D0/en
Publication of GB2448224A publication Critical patent/GB2448224A/en
Application granted granted Critical
Publication of GB2448224B publication Critical patent/GB2448224B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB0805991A 2007-04-02 2008-04-02 Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent Expired - Fee Related GB2448224B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0912941A GB2461412B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments
GB1008749A GB2468424B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90963707P 2007-04-02 2007-04-02
US95629607P 2007-08-16 2007-08-16
US95665707P 2007-08-17 2007-08-17

Publications (3)

Publication Number Publication Date
GB0805991D0 GB0805991D0 (en) 2008-05-07
GB2448224A GB2448224A (en) 2008-10-08
GB2448224B true GB2448224B (en) 2010-09-01

Family

ID=39409946

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0912941A Expired - Fee Related GB2461412B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments
GB0805991A Expired - Fee Related GB2448224B (en) 2007-04-02 2008-04-02 Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0912941A Expired - Fee Related GB2461412B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments

Country Status (11)

Country Link
US (8) US7718677B2 (enExample)
EP (4) EP2322168A1 (enExample)
JP (3) JP2010523587A (enExample)
KR (2) KR20110075044A (enExample)
CN (2) CN103977003A (enExample)
AU (1) AU2008232453B8 (enExample)
CA (1) CA2682323A1 (enExample)
ES (1) ES2521494T3 (enExample)
GB (2) GB2461412B (enExample)
IL (2) IL201269A (enExample)
WO (1) WO2008122049A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
EP2322168A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
JP2011520964A (ja) * 2008-05-23 2011-07-21 ユニバーシティ・オブ・サウス・フロリダ ニコチン性アセチルコリン受容体活性を有する化合物を用いる末梢感覚神経喪失の治療方法
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
BR112012013487A2 (pt) * 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US9119843B2 (en) 2009-12-04 2015-09-01 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
CA2807661C (en) * 2010-08-11 2019-09-10 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
BR122014023207A2 (pt) 2010-09-23 2019-05-28 Abbvie Inc. Compostos derivados de aza-adamantano, seus usos e processos para a preparação destes compostos
CA2815959C (en) 2010-11-01 2020-10-06 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
BR112013018726A2 (pt) * 2011-01-27 2016-10-25 Novartis Ag uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina
MX2013010698A (es) * 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
CA2841785A1 (en) * 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
WO2014134221A1 (en) * 2013-02-26 2014-09-04 Azhir Ari Compositions and methods for treatment in parkinson's disease patients
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2015168616A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use
JP6276429B2 (ja) * 2014-06-18 2018-02-07 イーライ リリー アンド カンパニー ペルゴリドの経皮製剤およびその使用
US9504645B2 (en) * 2014-10-20 2016-11-29 Oyster Point Pharma, Inc. Pharmaceutical formulations for treating ocular conditions
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
CN106138061B (zh) * 2015-04-03 2019-06-04 中国人民解放军第三军医大学第三附属医院 预防或减弱肺纤维化的复合物及其制剂和用途
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
EP3565637A1 (en) * 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Methods and devices for treating levodopa induced dyskinesia
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US20220401391A1 (en) * 2019-05-09 2022-12-22 Apkarian Tech Llc Methods and compositions for treating pain
FR3106978B1 (fr) 2020-02-11 2024-04-26 Olivier Petitjean Utilisation d'une molecule inhibitrice de la production de ros d'origine mitochondriale telle que l'anethole trithione pour traiter la maladie de parkinson
EP4399517A4 (en) * 2021-09-08 2025-10-15 Achieve Life Sciences Inc ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE
WO2023057650A1 (en) 2021-10-10 2023-04-13 Centre Hospitalier Universitaire Vaudois (Chuv) A method for predicting side effects of drugs and vaccines

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
WO1999066916A1 (en) * 1998-06-22 1999-12-29 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020002189A1 (en) * 1999-04-14 2002-01-03 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2007104575A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Stable lozenge compositions providing rapid release of nicotine
WO2007133141A1 (en) * 2006-05-16 2007-11-22 Mcneil Ab Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166159A (en) * 1875-07-27 Improvement in calcining-kilns
US77276A (en) * 1868-04-28 Improvement in spring and body braces for vehicles
US113452A (en) * 1871-04-04 Improvement in table-leaf supports
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4321387A (en) 1980-03-21 1982-03-23 Philip Morris, Incorporated Process for the preparation of optically active nicotine analogs
US4332945A (en) 1981-01-29 1982-06-01 Philip Morris, Incorporated Optically active nicotine analogs and process for their preparation
US4590278A (en) 1981-01-29 1986-05-20 Philip Morris Incorporated Nicotine analogs
US4442292A (en) 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4452984A (en) 1981-01-29 1984-06-05 Philip Morris, Inc. Optically active nicotine analogs and process for their preparation
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB8317576D0 (en) * 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4953572A (en) * 1985-04-25 1990-09-04 Rose Jed E Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4920989A (en) * 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE3645036A1 (de) * 1986-11-18 1989-01-05 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
ES2074441T3 (es) 1987-10-05 1995-09-16 Yamanouchi Pharma Co Ltd Compuestos espiro heterociclicos y su preparacion.
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
ES2153360T3 (es) 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
GB9200047D0 (en) * 1992-01-03 1992-02-26 Univ Alberta Nicotine-containing nasal spray
US5242934A (en) * 1992-03-02 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) * 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5248690A (en) * 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5703100A (en) 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
EP0853621A1 (en) 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
WO1997011073A1 (en) 1995-09-22 1997-03-27 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
ES2197255T3 (es) 1995-11-17 2004-01-01 MERCK & CO. INC. Nuevos compuestos de arilo sustituido utiles como moduladores de los receptores de acetilcolina.
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
ATE275394T1 (de) 1997-03-11 2004-09-15 Arakis Ltd R- und s- enantiomere getrennteteile enthaltende dosierungsformen
FR2761072B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP2002502383A (ja) 1997-05-30 2002-01-22 ニューロサーアチ・アクティーゼルスカブ ニコチンＡＣｈレセプターに於けるコリン作動性リガンドとしての９−アザビシクロ（３．３．１）ノン−２−エン及びノナン誘導体
AU744368B2 (en) 1997-05-30 2002-02-21 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
NZ500644A (en) 1997-05-30 2001-08-31 Neurosearch As Azacyclooctane and azacycloheptane derivatives useful as nicotinic ACh receptor modulators
TR199902942T2 (xx) 1997-05-30 2000-04-21 Neurosearch A/S Nikotinik ACh Resept�rlerinde kolinerjik ligandlar olarak 8-Azabisiklo(3.2.1)okt-ene ve okstan t�revleri.
FR2765874B1 (fr) 1997-07-09 1999-08-13 Synthelabo Derives de 6-pyrrolidin-2-ylpyrindines, leur preparation et leur application en therapeutique
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
DK1027336T3 (da) 1997-10-27 2005-01-24 Neurosearch As Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse
CA2306477A1 (en) 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
US6057446A (en) * 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
US6211194B1 (en) * 1998-04-30 2001-04-03 Duke University Solution containing nicotine
US6232316B1 (en) * 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
PT1107965E (pt) 1998-08-25 2004-10-29 Ortho Mcneil Pharm Inc Eteres e tioeteres de piridilo como ligantes para receptores de acetilcolina nicotinica e as suas aplicacoes terapeuticas
US6262124B1 (en) * 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
WO2000032600A1 (en) 1998-11-27 2000-06-08 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives
FR2786770B1 (fr) 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
ATE320711T1 (de) * 1998-12-16 2006-04-15 Univ South Florida Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
CN1345320A (zh) 1999-01-29 2002-04-17 艾博特公司 用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物
CN1348449A (zh) 1999-04-26 2002-05-08 神经研究公司 杂芳基二氮杂环烷烃及其制备方法和应用
DE60008866T2 (de) 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
US20040229908A1 (en) 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US8256433B2 (en) * 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2798065B1 (fr) * 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
JP2001261652A (ja) * 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
US6489025B2 (en) * 2000-04-12 2002-12-03 Showa Denko K.K. Fine carbon fiber, method for producing the same and electrically conducting material comprising the fine carbon fiber
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2002002081A1 (en) 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
GB0022084D0 (en) * 2000-09-08 2000-10-25 Univ Aberdeen Treatment of multiply antibiotic-resistant organisms
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
SE0102197D0 (sv) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
US20030087937A1 (en) * 2001-10-15 2003-05-08 Nils-Olof Lindberg Nicotine and cocoa powder compositions
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
SE0104388D0 (sv) 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7767698B2 (en) * 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
ATE359075T1 (de) * 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
SE0301320D0 (sv) 2003-05-06 2003-05-06 Astrazeneca Ab Positive modulators of nicotinic acetylcholine receptors
US20050159419A1 (en) * 2003-05-14 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
PL1663168T3 (pl) * 2003-09-08 2009-07-31 Mcneil Ab Preparaty nikotyny i ich zastosowanie
CA2553156A1 (en) * 2003-10-20 2005-05-12 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
CN1332667C (zh) * 2004-05-26 2007-08-22 中国科学院生物物理研究所 一种抗帕金森症（pd）复合制剂
RU2418797C2 (ru) * 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
JP2009514871A (ja) 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 薬学的に活性な物質の持続送達のためのカルボキシアルキルセルロースエステル
US7958887B2 (en) * 2006-03-10 2011-06-14 Aradigm Corporation Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations
EP2322168A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
WO1999066916A1 (en) * 1998-06-22 1999-12-29 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020002189A1 (en) * 1999-04-14 2002-01-03 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2007104575A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Stable lozenge compositions providing rapid release of nicotine
WO2007133141A1 (en) * 2006-05-16 2007-11-22 Mcneil Ab Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Nicotine affects striatal glutamergic function in 6-OHDA lesioned rats", C.K. Meshul et al, Advances in behavioural Biology, (2003) 54 (Basal Ganglia VI), 589-598 *
"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys", M.Quik et al, Annals of Neurology, (2007), 62(6), 588-596 *

Also Published As

Publication number Publication date
KR20100045406A (ko) 2010-05-03
US7718677B2 (en) 2010-05-18
JP2013155209A (ja) 2013-08-15
EP1977746A1 (en) 2008-10-08
GB2461412A (en) 2010-01-06
HK1147951A1 (en) 2011-08-26
US20100196463A1 (en) 2010-08-05
AU2008232453A1 (en) 2008-10-09
EP2322166A1 (en) 2011-05-18
US20100166735A1 (en) 2010-07-01
CN103977003A (zh) 2014-08-13
IL232200A0 (en) 2014-05-28
IL201269A0 (en) 2010-05-31
US20110077276A1 (en) 2011-03-31
WO2008122049A2 (en) 2008-10-09
EP1977746B8 (en) 2014-09-24
GB0912941D0 (en) 2009-09-02
CN101772346A (zh) 2010-07-07
HK1135037A1 (en) 2010-05-28
IL201269A (en) 2014-05-28
AU2008232453A8 (en) 2011-07-21
EP2322168A1 (en) 2011-05-18
GB0805991D0 (en) 2008-05-07
ES2521494T3 (es) 2014-11-12
GB2448224A (en) 2008-10-08
US20100158895A1 (en) 2010-06-24
GB2461412B (en) 2010-09-29
US20080260825A1 (en) 2008-10-23
AU2008232453B2 (en) 2011-06-23
KR101122469B1 (ko) 2012-07-12
JP2010523587A (ja) 2010-07-15
US20100159004A1 (en) 2010-06-24
HK1145978A1 (en) 2011-05-13
WO2008122049A3 (en) 2008-12-11
KR20110075044A (ko) 2011-07-05
US20160235732A1 (en) 2016-08-18
EP1977746B1 (en) 2014-07-30
AU2008232453B8 (en) 2011-07-21
US20100029723A1 (en) 2010-02-04
JP2016020385A (ja) 2016-02-04
CA2682323A1 (en) 2008-10-09
CN101772346B (zh) 2014-05-07
EP2322167A1 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
GB2448224B (en) Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
IL206159A0 (en) Oral pharmaceutical dosage forms
IL193727A0 (en) Dosage forms for administering combinations of drugs
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
IL199472A0 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
ZA200904436B (en) Modified release ibuprofen solid oral dosage form
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
GB0703507D0 (en) Solid pharmaceutical dose
IL185390A0 (en) A solid pharmaceutical dosage formulation
PL2457562T3 (pl) Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego
IL184394A0 (en) Bendamustine pharmaceutical compositions for lyophilisation
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
ZA201100615B (en) Appetising medicament for oral administration in solid form
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
TW200806282A (en) Solid dosage formulations
JP2009537554A5 (enExample)
ZA200705793B (en) Bendamustine pharmaceutical compositions for lyophilisation
ZA201105572B (en) Pharmaceutical composition for oral administration
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
GB0823069D0 (en) A process for the preparation of an orally administered unit dose tablet
GB0703674D0 (en) A Process For The Preparation of an Orally Administered Unit Dose Tablet
WO2008060546A3 (en) Oral formulations

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20160402